Abbisko Therapeutics
和誉医药
Executive Summary
Abbisko Therapeutics is a Hong Kong-listed Chinese biotech with clear BIOSECURE status, making it a viable partner for US pharma. However, limited public disclosure on pipeline assets, management team, and recent corporate activities suggests either early-stage development or strategic opacity. The Shanghai headquarters and Hong Kong listing indicate likely VIE structure requiring careful due diligence. Without visible pipeline data or recent deal activity, engagement should focus on information gathering before deal evaluation.
Structure: As a Hong Kong-listed Chinese biotech, Abbisko likely operates through a Variable Interest Entity (VIE) structure with offshore holding companies controlling mainland Chinese operating entities. The 2256.HK ticker indicates compliance with Hong Kong listing requirements, but multiple jurisdiction exposure requires careful review of IP ownership, regulatory filings, and operational control structures during due diligence.
BIOSECURE Risk
Company shows clear BIOSECURE status with no BCC designation, indicating current compliance with US regulatory restrictions
Key Exposures:
- •Potential future designation risk
- •Supply chain dependencies on restricted entities
- •Collaboration partnerships requiring review
Mitigation: Unknown - no public information available on specific BIOSECURE compliance measures or risk mitigation strategies
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent out-licensing or partnership activity identified in available records
Approach: Initial information-gathering approach through conference meetings or direct outreach to understand pipeline assets, development stage, and partnership interests before formal evaluation
Red Flags
- ⚠Limited public disclosure on pipeline and operations
- ⚠No visible management team information
- ⚠Absence of recent corporate activity or deal announcements
- ⚠Potential information transparency concerns for due diligence
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.